Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

Trial Profile

Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2013

At a glance

  • Drugs Tuberculosis vaccine (Primary) ; Antibacterials
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 19 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 19 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top